The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market consists of sales of anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings. The class of drugs includes Bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination drugs.
This report contains market size and forecasts of Anti-Asthmatics and COPD Drugs in Global, including the following market information:
Global Anti-Asthmatics and COPD Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Anti-Asthmatics and COPD Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Anti-inflammatory Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Anti-Asthmatics and COPD Drugs include Novartis AG, Merck & Co, GlaxoSmithKline, Boehringer Ingelheim Gmbh, AstraZeneca, Roche, Teva Pharmaceutical, Vectura and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Anti-Asthmatics and COPD Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anti-Asthmatics and COPD Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Anti-Asthmatics and COPD Drugs Market Segment Percentages, by Type, 2021 (%)
Anti-inflammatory Drugs
Monoclonal Antibodies
Combination Drugs
Global Anti-Asthmatics and COPD Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Anti-Asthmatics and COPD Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Anti-Asthmatics and COPD Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Anti-Asthmatics and COPD Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anti-Asthmatics and COPD Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Anti-Asthmatics and COPD Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis AG
Merck & Co
GlaxoSmithKline
Boehringer Ingelheim Gmbh
AstraZeneca
Roche
Teva Pharmaceutical
Vectura
Pfizer
Abbott
Mylan
Allergan
Cipla
Akorn